Antifungal Treatment • Allylamine Class

Buy Terbinafine Online — Fast, Effective Antifungal Treatment

Terbinafine is a highly effective antifungal medication available as tablets, cream, and gel. Used for fungal infections of the skin and nails, it offers strong results with a relatively short treatment course.

▼ Table of Contents

What Is Terbinafine?

Terbinafine Overview

Terbinafine is a systemic and topical antifungal medication belonging to the allylamine class, widely used for the treatment of dermatophyte infections affecting the skin, hair, and nails. As an allylamine antifungal, it demonstrates strong fungicidal activity by selectively inhibiting the enzyme squalene epoxidase, a key component in the fungal ergosterol synthesis pathway. This disruption leads to intracellular accumulation of squalene and structural instability of the fungal cell membrane, ultimately causing cell death and effective clearance of infection.

Terbinafine is available in several pharmaceutical forms, including oral tablets, topical cream, and gel formulations. Oral tablets are primarily used for nail fungus (onychomycosis) and more extensive dermatophyte infections, while topical forms are suitable for localized skin conditions such as tinea pedis, tinea cruris, and tinea corporis. The variety of formulations allows clinicians to tailor therapy based on infection severity, anatomical location, and patient-specific factors.

The medication is commonly prescribed for fungal infections caused by dermatophytes, including Trichophyton, Microsporum, and Epidermophyton species. Its high lipophilicity enables deep penetration into keratinized tissues, ensuring sustained therapeutic concentrations in the skin, subcutaneous layers, and nail plates. This pharmacological profile contributes to its reputation as a first-line therapy with high clinical and mycological cure rates, often requiring shorter treatment durations compared to other antifungal classes.

Due to its predictable absorption, strong tissue affinity, and prolonged persistence in keratin, terbinafine remains one of the most effective and widely used antifungal agents for both acute and chronic dermatophyte infections. Its combination of potent fungicidal action, multiple dosage forms, and broad clinical applicability makes it a cornerstone therapy in modern antifungal treatment.

How Terbinafine Works

Terbinafine acts through a well‑defined fungicidal mechanism that directly targets the integrity of the fungal cell membrane. As an allylamine antifungal, it selectively inhibits the enzyme squalene epoxidase, which is essential for the early stages of ergosterol synthesis. Ergosterol is a structural lipid required to maintain membrane stability, fluidity, and proper functioning of fungal cells. By blocking this enzymatic step, terbinafine disrupts a critical metabolic pathway that fungi cannot bypass.

The inhibition of squalene epoxidase leads to two simultaneous biochemical consequences. First, the synthesis of ergosterol sharply declines, weakening the fungal cell membrane and making it more susceptible to structural damage. Second, intracellular squalene accumulates to toxic concentrations. Elevated squalene levels interfere with membrane‑bound processes, induce osmotic imbalance, and ultimately compromise the cell’s ability to maintain homeostasis. This dual mechanism — depletion of ergosterol and buildup of squalene — creates a hostile intracellular environment that fungi cannot survive.

As a result of these combined effects, terbinafine does not merely slow fungal growth; it actively destroys fungal cells. This is why the drug is classified as a fungicidal agent rather than fungistatic. The structural collapse of the membrane, loss of viability, and irreversible metabolic failure lead to rapid fungal cell death, making terbinafine one of the most potent treatments for dermatophyte infections.

The efficiency of this mechanism explains terbinafine’s strong clinical performance in conditions such as tinea pedis, tinea corporis, and onychomycosis. Its ability to penetrate keratinized tissues and maintain high local concentrations further enhances its fungicidal action, ensuring sustained suppression of fungal growth and long‑lasting therapeutic outcomes.

Indications

Terbinafine is indicated for the treatment of a broad spectrum of superficial fungal infections affecting keratinized tissues, including the skin, nails, and hair. As a potent fungicidal allylamine, it demonstrates consistently high clinical and mycological cure rates across the most common dermatophyte‑associated conditions. Its mechanism of action, deep tissue penetration, and prolonged persistence in keratin make it a preferred first‑line therapy in both localized and extensive fungal infections.

One of the primary indications for terbinafine is onychomycosis, a chronic fungal infection of the fingernails or toenails. Oral terbinafine remains the gold‑standard treatment due to its ability to accumulate within the nail matrix and deliver sustained fungicidal concentrations. It is particularly effective against Trichophyton species, which account for the majority of nail infections. Treatment courses are typically shorter and more successful compared to alternative antifungal agents.

Terbinafine is also widely used for common dermatophyte infections of the skin, including tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm). These conditions often present with itching, scaling, erythema, and discomfort. Topical terbinafine provides rapid symptom relief and high eradication rates, while oral therapy may be considered for more persistent or widespread cases. Its fungicidal action ensures faster clearance compared to fungistatic alternatives.

In addition to dermatophyte infections, terbinafine is effective in managing pityriasis versicolor, a superficial yeast‑related disorder caused by Malassezia species. By reducing pathogenic fungal overgrowth and restoring the balance of normal skin flora, terbinafine helps normalize pigmentation and prevent recurrence. Its broad antifungal spectrum and favorable safety profile make it a versatile therapeutic option across multiple clinical scenarios.

Forms & Strengths

Terbinafine is available in several pharmaceutical forms designed to treat a wide range of superficial fungal infections affecting the skin and nails. Each formulation provides potent fungicidal activity through inhibition of squalene epoxidase, but the optimal choice depends on the infection’s location, severity, and depth of tissue involvement. The availability of both systemic and topical options allows clinicians to tailor therapy precisely to the patient’s needs, ensuring high cure rates and efficient symptom resolution.

The systemic formulation is supplied as 250 mg tablets, which remain the standard of care for onychomycosis and extensive dermatophyte infections. Oral terbinafine achieves high concentrations in keratinized tissues, including the nail matrix and nail bed, making it particularly effective for chronic or resistant nail disease. Its pharmacokinetic profile ensures prolonged persistence in nails even after treatment completion, supporting long-term mycological clearance.

For localized skin infections, terbinafine is available in several topical strengths: a 1% cream, 1% gel, and 1% spray. These formulations are commonly used for tinea pedis, tinea cruris, and tinea corporis, where they provide rapid symptom relief and high eradication rates. The cream is typically preferred for dry or scaly lesions, the gel for areas requiring faster absorption, and the spray for hard-to-reach or moist regions such as interdigital spaces. All topical forms deliver concentrated antifungal action directly to the affected area with minimal systemic exposure.

Together, these strengths and formulations offer comprehensive coverage across superficial mycoses, ensuring flexibility in treatment selection while maintaining consistently high clinical effectiveness. Whether used orally for deep nail involvement or topically for localized skin infections, terbinafine provides a reliable and well‑established therapeutic option in modern antifungal therapy.

Onset & Duration

Terbinafine begins acting early in the treatment course, as its fungicidal mechanism is triggered shortly after therapy is initiated. By inhibiting squalene epoxidase and disrupting ergosterol synthesis, the drug rapidly compromises fungal cell membrane integrity. Patients with superficial skin infections such as tinea pedis, tinea cruris, or tinea corporis often notice the first signs of improvement within the initial several days of therapy. Symptoms like itching, redness, and scaling typically diminish quickly, reflecting early suppression of fungal activity rather than complete eradication.

The total duration of treatment depends on the type and depth of the infection. Topical terbinafine (1% cream, gel, or spray) is usually applied for a relatively short period — often from one to two weeks — because superficial dermatophyte infections respond rapidly to localized fungicidal concentrations. In contrast, oral terbinafine 250 mg requires a longer course, especially for onychomycosis, where the pathogen resides deep within the nail plate and nail bed. Oral therapy typically lasts several weeks to ensure complete elimination of the fungus and to reduce the risk of recurrence.

Despite the drug’s rapid antifungal action, visible improvement in nail appearance occurs much more slowly. Nails grow at a gradual pace, and full cosmetic recovery depends on the natural regrowth cycle rather than ongoing infection. For toenails, complete replacement may take 6–12 months, while fingernails generally require a shorter period. Even after the oral course is finished, the nail continues to grow out healthy tissue, gradually replacing the previously infected areas. This delayed visual response is normal and reflects physiological nail turnover rather than treatment failure.

Effectiveness

Terbinafine is widely recognized for its strong clinical performance across a broad range of dermatophyte infections, demonstrating consistently high cure rates and reliable pathogen eradication. Its fungicidal mechanism — direct inhibition of squalene epoxidase — allows the drug to eliminate fungi rather than merely suppress their growth. This contributes to rapid symptom improvement and durable mycological clearance, particularly in conditions such as onychomycosis, tinea pedis, tinea cruris, and tinea corporis. Across clinical practice, terbinafine maintains one of the highest overall cure rates among systemic and topical antifungal therapies.

A key advantage of terbinafine is its ability to sustain therapeutic concentrations in keratinized tissues long after treatment ends. This prolonged persistence significantly reduces the likelihood of reinfection and contributes to a notably low relapse rate. Patients treated with terbinafine typically experience fewer recurrences compared with those receiving fungistatic alternatives, as the drug continues exerting antifungal pressure during the natural regrowth of skin and nails. This extended post‑treatment activity is especially important in onychomycosis, where slow nail growth can otherwise allow residual fungal elements to reestablish infection.

When compared with itraconazole, terbinafine consistently demonstrates superior outcomes in dermatophyte‑related nail infections. Its deeper penetration into the nail bed, stronger fungicidal action, and longer tissue retention translate into higher mycological and clinical cure rates. Itraconazole remains effective for certain non‑dermatophyte infections, but for classic dermatophyte onychomycosis, terbinafine generally provides more reliable and sustained results. This comparative advantage reinforces its role as a first‑line therapy in modern antifungal treatment guidelines.

Overall, terbinafine’s combination of high cure rates, low relapse rates, and superior performance relative to itraconazole makes it one of the most effective and trusted antifungal agents for superficial mycoses. Its predictable pharmacokinetics and strong clinical track record continue to support its widespread use in both primary care and dermatology settings.

Safety Summary

Terbinafine is generally considered a well‑tolerated antifungal agent, with the majority of adverse effects classified as mild, transient, and self‑limiting. Most patients experience no significant discomfort during therapy, and when side effects do occur, they typically involve predictable, non‑serious reactions. Among the common side effects are gastrointestinal symptoms such as nausea, abdominal discomfort, or diarrhea, as well as headache and nonspecific fatigue. Some individuals may also report temporary alterations in taste or smell, which usually resolve after discontinuation of therapy. These reactions reflect the drug’s systemic activity but rarely require medical intervention.

Although uncommon, terbinafine has been associated with rare but clinically important adverse events, the most notable of which is hepatotoxicity. Liver‑related reactions can range from asymptomatic elevations in liver enzymes to more serious hepatic injury. Because of this, oral terbinafine is typically avoided in individuals with active or chronic liver disease, and prolonged systemic therapy may warrant periodic liver function assessment. Severe skin reactions, hypersensitivity responses, or persistent taste disturbances are also rare but documented events.

Terbinafine is contraindicated in patients with known hypersensitivity to allylamine antifungals, as well as those with significant hepatic impairment or conditions that may affect drug metabolism. Individuals with chronic liver disorders, severe systemic illnesses, or a history of adverse reactions to similar antifungal agents are generally advised to avoid systemic terbinafine. Topical formulations may be considered in some cases, as they have minimal systemic absorption, but systemic therapy remains unsuitable for high‑risk groups. Overall, terbinafine maintains a strong safety profile when used appropriately, with serious adverse effects occurring only in a small minority of patients.

Interactions Summary

Terbinafine has a well‑characterized interaction profile, and understanding these factors is essential for safe use, especially during systemic therapy. One of the most clinically relevant aspects of its pharmacology is its effect on the CYP2D6 metabolic pathway. Terbinafine acts as a moderate inhibitor of CYP2D6, which can lead to increased plasma concentrations of medications that rely on this enzyme for clearance. These include certain antidepressants, beta‑blockers, antiarrhythmics, and some antipsychotics. In susceptible patients, elevated drug levels may enhance therapeutic effects but also increase the risk of adverse reactions, making dose adjustments or closer monitoring advisable during co‑administration.

Alcohol consumption is another important consideration during terbinafine therapy. Both terbinafine and ethanol are metabolized in the liver, and concurrent use can increase hepatic strain. While moderate alcohol intake is not strictly contraindicated, limiting consumption is recommended to reduce cumulative hepatic burden. This precaution is especially relevant for individuals undergoing prolonged oral therapy, where sustained metabolic activity may heighten the risk of liver‑related side effects. Patients should be advised to monitor for symptoms such as fatigue, dark urine, or right‑upper‑quadrant discomfort, which may indicate hepatic stress.

Individuals with pre‑existing liver disease or impaired hepatic function require particular caution. Systemic terbinafine is generally avoided in these patients due to reduced metabolic clearance and a significantly increased risk of hepatotoxicity. Conditions such as chronic hepatitis, cirrhosis, or unexplained persistent liver enzyme elevations represent strong reasons to avoid oral terbinafine altogether. Topical formulations may be considered as safer alternatives, as they exhibit minimal systemic absorption, but systemic therapy remains contraindicated in high‑risk groups. Understanding these interaction principles helps ensure safe, effective, and individualized use of terbinafine across diverse clinical scenarios.

Clinical Evidence Summary

Terbinafine has been extensively evaluated in numerous clinical trials, forming one of the strongest evidence bases among systemic antifungal agents. Research consistently demonstrates its potent fungicidal activity, deep tissue penetration, and sustained therapeutic concentrations in keratinized structures such as skin and nails. These pharmacological advantages translate into high clinical and mycological cure rates across a wide range of dermatophyte infections. Key studies highlight its effectiveness in both short‑term symptom resolution and long‑term eradication of fungal pathogens, reinforcing its role as a first‑line therapy in modern dermatology.

In placebo‑controlled trials, terbinafine has shown markedly superior outcomes, with significantly higher mycological cure rates and faster clinical improvement. Patients receiving terbinafine consistently achieved higher rates of complete pathogen clearance compared with placebo, often demonstrating early symptom reduction within the first weeks of therapy. These findings confirm that terbinafine’s fungicidal mechanism provides a decisive therapeutic advantage, particularly in infections caused by Trichophyton species, which are responsible for the majority of nail and skin mycoses.

Comparative studies further demonstrate terbinafine’s superiority over itraconazole, especially in the treatment of onychomycosis. Trials show higher cure rates, lower relapse rates, and more durable long‑term outcomes with terbinafine. Its ability to maintain therapeutic concentrations in the nail plate long after treatment completion contributes to sustained pathogen suppression and reduced recurrence. While itraconazole remains effective for certain non‑dermatophyte infections, terbinafine consistently outperforms it in classic dermatophyte onychomycosis, making it the preferred systemic option for most patients.

Overall, the clinical evidence strongly supports terbinafine as a highly effective antifungal therapy, offering superior cure rates compared with placebo and demonstrating clear advantages over itraconazole in dermatophyte nail infections. Its robust evidence base continues to guide treatment recommendations and reinforces its position as a cornerstone therapy in the management of superficial mycoses.

Who Should Use Terbinafine

Terbinafine is primarily recommended for adults who require effective treatment for dermatophyte infections affecting either the skin or the nails. Its fungicidal mechanism, deep tissue penetration, and strong clinical track record make it a preferred first‑line therapy in cases where rapid pathogen eradication and durable outcomes are essential. Adults with persistent or recurrent fungal infections often benefit from terbinafine due to its ability to maintain therapeutic concentrations in keratinized tissues long after treatment has ended, providing extended protection against relapse.

One of the groups that benefits most from terbinafine therapy is patients with onychomycosis, a chronic fungal infection of the fingernails or toenails. Oral terbinafine 250 mg is considered the gold standard for this condition because it penetrates deeply into the nail matrix and nail bed, delivering sustained fungicidal activity. Individuals with thickened, discolored, brittle, or distorted nails caused by dermatophytes typically experience significant improvement with terbinafine, both in terms of pathogen clearance and long‑term cosmetic recovery. Because nails grow slowly, these patients require a systemic agent capable of maintaining prolonged antifungal pressure — a role terbinafine fulfills exceptionally well.

Terbinafine is also widely used by adults with skin mycoses, including tinea pedis, tinea cruris, and tinea corporis. For these conditions, topical formulations such as 1% cream, gel, or spray provide rapid symptom relief and high eradication rates. Patients experiencing itching, redness, scaling, or ring‑shaped lesions often respond quickly to topical terbinafine, making it an ideal choice for localized infections. In more extensive or resistant cases, systemic therapy may be considered to ensure complete pathogen elimination.

Overall, terbinafine is well suited for adults seeking a reliable, evidence‑based antifungal treatment with proven effectiveness across both nail and skin infections. Its versatility, strong clinical outcomes, and favorable safety profile make it a cornerstone therapy for managing superficial mycoses in everyday clinical practice.

Who Should Avoid Terbinafine

Terbinafine is an effective antifungal medication, but it is not appropriate for all patient groups. Individuals with severe hepatic impairment are generally advised to avoid systemic terbinafine entirely. Because the drug is metabolized in the liver, reduced hepatic function can lead to impaired clearance, accumulation of the medication, and a significantly increased risk of hepatotoxicity. Patients with cirrhosis, chronic hepatitis, or unexplained persistent liver enzyme elevations fall into a high‑risk category where the safety margin of oral terbinafine becomes substantially reduced. Even mild hepatic abnormalities may warrant careful evaluation before therapy is initiated.

Another group that should avoid terbinafine includes individuals with a known allergy to allylamine antifungals. Although hypersensitivity reactions are uncommon, they can manifest as rash, urticaria, swelling, or more severe immune‑mediated responses in susceptible patients. Anyone with a documented allergy to terbinafine or related allylamines should avoid both systemic and topical formulations to prevent recurrence of hypersensitivity symptoms. Alternative antifungal classes may be considered in such cases to ensure safe and effective therapy.

Use of terbinafine during pregnancy requires particular caution. While topical formulations have minimal systemic absorption, systemic terbinafine is generally avoided unless the potential therapeutic benefit clearly outweighs the potential risk. Data on oral terbinafine use in pregnancy remain limited, and clinicians typically recommend postponing systemic treatment until after pregnancy when possible. If therapy is necessary, it should be undertaken only under medical supervision, with careful assessment of maternal and fetal considerations.

Overall, terbinafine is a well‑established antifungal agent, but its use must be individualized. Patients with severe liver disease, those with hypersensitivity to allylamines, and pregnant individuals requiring systemic therapy represent groups for whom terbinafine may not be appropriate. Understanding these limitations helps ensure safe, responsible, and clinically appropriate use of the medication.

Terbinafine vs Lamisil

Terbinafine and Lamisil represent two versions of the same antifungal therapy, as both contain the identical active ingredient — terbinafine hydrochloride. This means that their pharmacological action, fungicidal mechanism, tissue penetration, and overall clinical performance are fundamentally the same. Regardless of whether a patient uses the generic formulation or the branded product, the therapeutic effect on dermatophyte infections remains equivalent. Both options inhibit squalene epoxidase, disrupt ergosterol synthesis, and deliver strong antifungal activity across skin and nail infections.

The most notable distinction between the two lies in their price. Lamisil, being the branded version, is typically more expensive due to branding, marketing, and packaging factors. Generic terbinafine, on the other hand, offers the same active substance and clinical effectiveness at a significantly lower cost. This price difference becomes especially relevant for long‑term therapy, such as oral treatment for onychomycosis, where extended courses may be required to achieve full pathogen eradication and support healthy nail regrowth.

In terms of effectiveness, clinical studies consistently show no meaningful difference between generic terbinafine and Lamisil. Cure rates, relapse rates, and safety profiles are comparable across both formulations. Patients with onychomycosis, tinea pedis, tinea cruris, or tinea corporis can expect the same therapeutic outcomes regardless of which version they use. For most individuals, generic terbinafine provides a cost‑effective, reliable, and clinically equivalent alternative to the branded product, making it the preferred choice in routine dermatological practice.

Ultimately, the decision between terbinafine and Lamisil often comes down to affordability and availability rather than differences in medical performance. Since both deliver identical antifungal action, patients and clinicians can confidently choose the option that best aligns with treatment duration, budget, and accessibility.

Terbinafine vs Other Antifungals

Terbinafine is frequently compared with other systemic antifungal agents, particularly itraconazole and fluconazole, as these medications are also used to treat dermatophyte and yeast infections. Despite belonging to different pharmacological classes, these drugs share overlapping indications, making comparative evaluation clinically important. Terbinafine, an allylamine antifungal, provides direct fungicidal activity, while itraconazole and fluconazole — both azole antifungals — are primarily fungistatic against dermatophytes. This mechanistic difference significantly influences cure rates, relapse rates, and overall treatment predictability.

When compared with itraconazole, terbinafine consistently demonstrates higher mycological and clinical cure rates, especially in onychomycosis. Itraconazole remains effective for certain non‑dermatophyte molds and Candida infections, but for classic dermatophyte nail disease, terbinafine’s deeper nail‑bed penetration and prolonged tissue persistence provide a clear advantage. Patients treated with terbinafine typically experience lower relapse rates, as the drug continues to exert antifungal pressure long after therapy ends. This sustained activity is particularly valuable in toenail infections, where slow nail growth increases the risk of recurrence if the pathogen is not fully eradicated.

In contrast, fluconazole is generally less effective against dermatophytes because it is fungistatic rather than fungicidal in this context. While fluconazole is highly effective for Candida infections and certain yeast‑related conditions, its performance in dermatophyte onychomycosis is less predictable. Treatment courses are often longer, cure rates lower, and relapse rates higher compared with terbinafine. For this reason, fluconazole is usually reserved for patients who cannot tolerate terbinafine or itraconazole, or for infections where Candida is the primary pathogen.

Overall, terbinafine’s strong fungicidal mechanism, high cure rates, and low relapse rates make it the preferred first‑line therapy for dermatophyte infections of the skin and nails. Itraconazole and fluconazole remain valuable alternatives in specific clinical scenarios, but neither consistently matches terbinafine’s effectiveness in treating dermatophyte‑related disease.

Terbinafine Summary Table

Form Strength Typical Course Effectiveness Common Side Effects
Tablet 250 mg 6–12 weeks (nails) High cure rate; low relapse GI upset, headache, taste changes
Cream 1% 1–2 weeks (skin) Rapid symptom relief Local irritation, redness
Gel 1% 1–2 weeks (skin) High topical penetration Mild burning or dryness
Spray 1% 1–2 weeks (skin) Convenient coverage for large areas Local irritation

Terbinafine FAQ

Treatment duration depends on the infection: skin infections usually require a short course, while nail infections require a longer regimen to fully eliminate the pathogen.

Terbinafine shows high mycological cure rates and is considered one of the most effective treatments for dermatophyte-related onychomycosis.

Skin infections often improve within the first days of therapy. Nail infections take longer, as visible improvement depends on new nail growth.

Full nail regrowth may take several months, as nails grow slowly. This reflects natural regrowth rather than ongoing infection.

Common effects include gastrointestinal discomfort, headache, and temporary changes in taste or smell.

Rare but serious reactions include liver-related adverse effects, which require medical attention if symptoms such as fatigue or dark urine appear.

Alcohol should be limited due to combined liver strain, as both terbinafine and ethanol are metabolized hepatically.

A missed dose should be taken when remembered unless it is close to the next scheduled dose.

Terbinafine affects drugs metabolized by CYP2D6, potentially altering levels of certain antidepressants, beta‑blockers, and antiarrhythmics.

Systemic terbinafine is not recommended for individuals with active or chronic liver disease due to increased risk of adverse reactions.

Use during pregnancy should be approached cautiously, and systemic therapy is generally avoided unless clearly necessary.

Terbinafine generally shows higher cure rates and lower relapse rates in nail infections compared with itraconazole.

Fluconazole is fungistatic against dermatophytes, while terbinafine is fungicidal, leading to faster and more complete pathogen eradication.

Yes, topical terbinafine is commonly used for tinea pedis and provides rapid symptom relief.

Terbinafine’s prolonged tissue persistence contributes to lower relapse rates compared with several alternative antifungals.

Yes, terbinafine is effective for tinea corporis and is often used as a first‑line therapy.

Yes, topical terbinafine is effective for tinea cruris and typically provides rapid improvement.

Terbinafine may help reduce fungal overgrowth in pityriasis versicolor, though other agents are sometimes preferred depending on severity.

It inhibits squalene epoxidase, causing toxic squalene accumulation and disrupting fungal cell membrane synthesis.

Oral terbinafine is more effective for nail infections, while topical formulations are suitable for localized skin infections.

Combination therapy is sometimes used in resistant cases, but terbinafine alone is sufficient for most dermatophyte infections.

Terbinafine persists in skin, hair, and nails for weeks after therapy, contributing to sustained antifungal activity.

Terbinafine is primarily active against dermatophytes; activity against yeasts varies and depends on the species.

Long-term use is generally limited to nail infections and should be monitored due to potential liver-related effects.

Monitoring may be considered during prolonged systemic therapy, particularly in individuals with risk factors for liver dysfunction.